Secondary Logo

Journal Logo

Survival benefit of pancreatic metastasectomy of clear cell renal cell carcinoma

Fang, Yuan1; Tang, Min2; Zhou, Wen-Tao1; Lou, Wen-Hui1

Section Editor(s): Lyu, Peng

doi: 10.1097/CM9.0000000000000500
Clinical Observations
Open

1Department of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China

2Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.

Correspondence to: Prof. Wen-Hui Lou, Department of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, ChinaE-Mail: lou.wenhui@outlook.com

How to cite this article: Fang Y, Tang M, Zhou WT, Lou WH. Survival benefit of pancreatic metastasectomy of clear cell renal cell carcinoma. Chin Med J 2019;00:00–00. doi: 10.1097/CM9.0000000000000500

Received 29 July, 2019

Yuan Fang and Min Tang contributed equally to the work.

Online date: November 7, 2019

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0

The clear cell renal cell carcinoma (ccRCC) appears to have a predilection for metastasizing to the pancreas.[1] In the recent years, there are increasing numbers of clinical series from Europe and the United States that demonstrate encouraging survival results of pancreatic metastasectomy,[2] but there are a few clinical data or only some case reports from East Asian population,[3] and there are no specific guidelines regarding the appropriate management. The objective of this study was to present our experience of pancreatic metastasectomy from ccRCC by reporting the peri-operative and survival outcome.

The Ethical Committee of Zhongshan Hospital, Fudan University approved this study. The patients signed the informed consent for research at the time of the surgery. We used a prospectively maintained surgical database to identify all ten patients with pancreatic metastasis of ccRCC from July 15, 2007 to April 9, 2019. The data retrieved included patient demographics, origin of the primary tumor, time interval prior to pancreatic metastasectomy, type of pancreatic surgery, post-operative complication, and survival. Overall survival after pancreatic surgery was calculated from the time of the pancreatic metastasectomy surgery to cancer-related death or the last follow-up day. Statistical analysis was performed using the Statistical Package for the Social Sciences for Windows, version 20.0 (SPSS, Inc., Chicago, IL, USA). Survival analysis was implemented using life tables and Kaplan-Meier analysis.

The primary ccRCC lesions including right kidney in six patients and left kidney in four patients, with six males and four females, were resected in all cases. The median size of the ccRCC was 5.5 cm (2–10 cm), with nine TNM (tumor, node, metastasis) stage II and one stage III patients. Only one patient accepted the interferon treatment after renal surgery. Cases 8 and 10 were diagnosed as recurrent contralateral ccRCC and treated with partial nephrectomy at 2.0 and 65.9 months before the pancreatic metastasis. Moreover, solitary left lung metastasis was developed in case 7, 4.1 months before the pancreatic metastasis, and it was treated with left upper lobectomy.

The proportion of pancreatic metastasis of ccRCC in all the pancreatic malignancies from 2007 to 2019 was about 0.5% (10/2000). The median age of the total ten patients was 58.7 years (range: 51.0–68.0 years) at the time of pancreatic surgery. Only two of them had the chief complaint of upper abdominal pain, the rest eight of them were asymptomatic and diagnosed based on the routine abdominal imaging surveillance. All the computed tomography imaging showed the hyper-vascular and intense homogeneous contrast enhancement in the arterial phase, greater than normal pancreatic parenchyma, and a tendency to pass undetected in more delayed post-contrast phases.

Clinicopathologic characteristics of the ten cases of pancreatic metastatic ccRCC are shown in Table 1. The median time interval from the initial renal carcinoma surgery to the emergence of the pancreatic metastasis was 73.4 months (range: 4.4–182.7 months). Pancreatic metastasis was solitary in nine cases and multifocal in one case and existed in the head in four cases, body-tail in five cases, head with body-tail in one case. The median size of the pancreatic metastasis was 2.4 cm (range: 0.9–4.9 cm). Operative procedure was R0 resection, with distal pancreatectomy in five cases, pancreaticoduodenectomy in four cases, total pancreatectomy in one case. Grade B and grade C of post-operative pancreatic fistula were observed in case 2 and case 5, respectively. There was no peri-operative mortality. From the immunohistochemistry staining, carbonic anhydrase 9 (CA-9[+]) and paired box gene 8 (PAX8[+]) were indicative of ccRCC, while synaptophysin (SYN[−]), neuronal cell adhesion molecules 56 (CD56[−]), and chromogranin A (CGA[−]) could differentiate from the neuroendocrine tumors.

Table 1

Table 1

The median follow-up time was 59.6 months (range: 0.7–99.1 months). Three and a half months after the pancreatic surgery was performed, liver metastasis existed in the patient (case 3) and was treated by transarterial chemoembolization. In case 2 with the multifocal pancreatic metastasis, six cycles of chemotherapy of 5-fluorouracil combined with gemcitabine was implemented, while in case No. 7 sorafenib and case No. 10 pazopanib was orally taken respectively. All the other patients did not receive any post-operative treatment. Until the last follow-up day, six patients still alive and four patients died. The median overall survival after pancreatic metastasectomy was 77 months, with 1-,3-, and 5-year survival rate 100%, 100%, and 60%, respectively.

The survival of our study revealed that six of the total ten patients still alive, the median survival after pancreatic metastasectomy was 77 months, indicating the very significant survival benefit of the surgical resection. Moreover, an Italian large-sample multicenter study of 103 patients turned out that there was no significant survival difference between pancreatic resection versus tyrosine kinase inhibitors.[4] Therefore, more large-sample, multi-institutional studies should be implemented to confirm the survival benefit of surgical resection over non-surgical treatment.

Moreover, the peri-operative outcomes in the current study were satisfactory with no peri-operative mortality and only two patients had the complication, with morbidity only 2/10. Therefore, it is considered feasible and safe to perform the pancreatic metastasectomy especially in the high-volume pancreatic centers. However, whether or not to perform the typical or atypical pancreatic surgery is still controversial, because some studies showed that only digging out the metastatic lesions could protect the exocrine and endocrine function of the pancreas,[5] let alone the relatively indolent tumor phenotype of metastatic ccRCC.

Besides, this study has some limitations. Firstly, because pancreatic metastasis from ccRCC is a rare disease, it is difficult to implement the clinical trial in a prospective manner. Secondly, the post-operative regimen both after the primary renal surgery and pancreatic metastasectomy were not standard. Thirdly, due to the single-center experience and relatively small sample size, it is difficult to analyze the prognostic risk factors.

In summary, long-term survival may be achieved in some patients of ccRCC pancreatic metastasis through pancreatic metastasectomy with satisfactory morbidity. However, the decision of pancreatic metastasectomy should be carefully and systematically evaluated according to the specific condition of the patients.

Back to Top | Article Outline

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patients have given their consent for their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Back to Top | Article Outline

Funding

This study was supported by a grant from the National Natural Science Foundation of China (No. 81702964).

Back to Top | Article Outline

Conflicts of interest

None.

Back to Top | Article Outline

References

1. Tosoian JJ, Cameron JL, Allaf ME, Hruban RH, Nahime CB, Pawlik TM, et al. Resection of isolated renal cell carcinoma metastases of the pancreas: outcomes from the Johns Hopkins Hospital. J Gastrointest Surg 2014; 18:542–548. doi: 10.1007/s11605-013-2278-2.
2. Zerbi A, Ortolano E, Balzano G, Borri A, Beneduce AA, Di Carlo V. Pancreatic metastasis from renal cell carcinoma: which patients benefit from surgical resection? Ann Surg Oncol 2008; 15:1161–1168. doi: 10.1245/s10434-007-9782-0.
3. Dong J, Cong L, Zhang TP, Zhao YP. Pancreatic metastasis of renal cell carcinoma. Hepatobiliary Pancreat Dis Int 2016; 15:30–38. doi: 10.1016/S1499-3872(16)60052-8.
4. Santoni M, Conti A, Partelli S, Porta C, Sternberg CN, Procopio G, et al. Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. Ann Surg Oncol 2015; 22:2094–2100. doi: 10.1245/s10434-014-4256-7.
5. Kalra S, Atkinson BJ, Matrana MR, Matin SF, Wood CG, Karam JA, et al. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU Int 2016; 117:761–765. doi: 10.1111/bju.13185.
© 2019 by Lippincott Williams & Wilkins, Inc.